first and quarter Paul, earnings conference joining our call. everyone, Thanks, welcome,
for the including to key well results, it we Patrick first our look across our over I the today, of during before our headwinds impacting the our top-line as Q&A. at update X strategic Then I will for turn some pillars as will a drive financial our open more the results quarter, call progress up call progress On discuss to XXXX growth. on for and detailed outlook our
first year-over-year. growth approximately of our from product included results. line $XX.X $X.X revenue, X% revenue of with quarter Luminex. million We representing This from total million of Starting the achieved acquired
Excluding CNY our acquisition-related million. revenue, accounted organic revenue for XX.X
with the While particularly we throughout in China, APAC saw quarter. at with faced in the U.S. and biotech growth increasing base we notable strong and quarter, pharma of the Europe in our customer pressures growth the end
spending factors biotech a demand marked the shortly. quarter the resulting demand, pharma and uncertainties Patrick covered more in results in were on provide funding, will affecting our and orders. Among companies, financial slowdown detail cycles sales decline and macroeconomic delayed longer the reduced among a in biotech in
now QX well year. million our million, on $XXX of Based we prior headwinds, as representing the full results these $XXX to year the expect XX% revenue in as XX% over of to growth range
platform previous diversifying performance. growth remains While remain will the streams to than believe our FSP profiling top-line for strong to expectations, our our underlying our our we spectrum strong. slower driving this growth be year overall demand revenue continue and or full firmly We committed
efforts we transition XXXX business in newly in are our this Luminex We integrate from further operations strategy. year to with ongoing measures optimize business proactive to taking as acquired our the overall
as pride end-to-end and customers application comprehensive in the industry in solution offer divisions, distinctive take we we Cytek, offerings. that software, includes instruments, a our At position
to portfolio, our partnerships allowing apart Our the recent strengthened have acquisition us further field. in stand further and
for the spectrum sale of competent of choice method profiling platform of advance Our products adoption suite services and the analysis., continued full to as have Cytek's
resolve uniquely workflow a assay the portfolio to designed challenging models our flow cytometers for needs use meet FSP to of part analysis, technology, there is sales market converted Cytek's to of because in to into is ultra-high analysis of of to positioned complexity. suite regardless a corporations Our large ease it's of instruments more solid demand whether or sensitivity conventional needed core be all sale continues see waiting
our In of optimized portfolio our the will new recent on imaging our adoption advance use instruments FSP's and to expanding Luminex acquisition will addition, panels open for markets of cytometry and flow and applications. from continue business
These instruments, offer now execution. have purposeful I lay out pillars, power of and key we in informatics each applications, strategy first under offering map according and instruments. Starting our peers, in long-term faced road our which overall intentional executes our business these and on is the will aligned works to discussed the we our growth that business and which I integral before, X excellent are with to As clinical, our pillars our growth. future term. Despite with longer daily the quarter, over produce challenges the for confident remain X
now has of During instruments XXXX. we Cytek's as Altogether, XX of instruments. quarter first reached this quarter, placed the install X,XXX base Cytek
These than more achieve instruments XX applications. cell placements high lines countries. we product which Guava to X,XXX growth range and does of has in over applications customers analysis base include the Amnis not entry-level the core of installed and X,XXX our number Luminex, to from across reflect strategy This instruments imaginal users acquired of than an across the more from in-store
into base Over will term, replacement installed eventually from and this upgrades and benefit the Lights Northern our platforms. believe we longer Aurora
have that receptive for launch this also we will Luminex. sites to the instruments a Cytek's market by intend installed years from expanded advanced new future technologies technologies, We augmented believe based on base in with are provide we acquired powerful
our The divisions applications includes and trade. area
develop partners product Regions Here, our progress portfolio areas. are both for focused offerings, we more accurate. making of kits, in easier, which our relations expand application-specific the and scientist's and Revenue and the clinician's we our on increasing our collaborating and to continues highlighting faster, from and with making growth be are to demand area, actively work kits are fastest
our enhance high-parameter cell grow opportunities by our with Laboratories on to in investing reagent strategically to partnership and as strategic analysis systems. our are portfolio exemplified panels We expand Bio-Rad
The advantage are multi-parameter to for major our FSP quarter, addition excited and conducting partnership. about provides we StarBright of Bio-Rad a ongoing this announced which we researchers during first Dyes platform, the experiments
launched sales. We discovery, and power company's on sensitive in widely clinical AML panels new This immune cytometry unleashed also detecting and power recently evaluating pioneering identifying built research, or trial, normal and for SFP the Immunophenotyping our abnormal clinical full system. used myeloid and the comprehensive and and AML offer Multi-parametric effective characterizing assets cytometric year drug and technology flow X samples. retable diagnostics. our leukemia monitoring acute in AML of approach to the residual the MRD disease are panel extensive understanding revolutionizing and more a flow cytometry special experience human translational in of
used greater markers are tubes to sample AML into the Historically, for assessing redundant due on markers typically of volume. detection limitation and of multiple use conventional split the the channels, frocytometers, forcing
of preparation and kind divisions. use laboratory preserving ending labor single-tube with acquisition well as pressure sensitivity for practice, for sample clinical Our samples, increases enhancing by saving and redundant waste of and AML the while as time operational efficiency eliminating
therapies. we areas leverage and By and the providing of discoveries such specific life-saving jumpstart scientists to are as researchers giving advance solutions their total new development MRD, for application
informatics their enabling strategy to is customers of our our is area. our key bioinformatic streamline workflow. Our A third experiment part strategic
other of a the and with panel customers. with spectrum site suite design ability of design tools share full product Our cloud faster panels allows to to site panels customers
users. of can users special sales expanded any can creates the our analysis In our increases to that with providing templates attractiveness among addition, customers on convert be software. We the cited panels our believe into used drives instruments and benefits solutions, demand flow these loyalty
cloud launched late customer very site our adopted many continues customers by rapidly receive growing and year product Our of was last to interest.
by in for China where are and for of our the European the our seafloor our Northern reagents. common clinical now Lights use applications Turning opportunity. both clinical clinical to most system Several CLC is sale products approved Union, accompanied
our plan diagnostic detailed for doctors benefit platform, we a by clearance and be to where we visibility a power enhanced patients the of FDA clearer view As in condition. reminder, U.S. powerful patient's FSP giving believe products more of and approved, will submit each our the if to
patients, As in are LDG by the This is into our because sample system in new detailed doctors, with provides complete sales and small subtypes doctors to the recognition alike. is the Globally, multiparameter a market clinical conditions. or technology immunophenotyping believe difficult to the obtain tool customer of critical And business approach often the approach for with disease ability important and our to samples clinical EU, project in an only lapses one and single amount, our and attractive pathways. on samples the their also long-term amounts and driven refined to we results that China laboratory-developed more patients' limited labs to perform to patient test U.S. insights enables clinical represents and high-level being the of opportunity market Cytek. efficiently identify
plan the years when technology technology. to our In beginning adopted expected success is we a X very have concrete way, the full in had spectrum clinical revolutionized mirror market ago to we the with research market our
future. recognized and as we for establish spectrum the standard yields rapidly it clinical full plan was in Our research technology gold the as to applications the for bearer standard
one progress success all our here. benefits standard in area, other have will the a acceptance diagnostic correlation we can in any clinical approaches China of are tube, Europe, accelerated better in by are able clinical full we define maintaining become making customers clinical comments in single being We community just the known these platform more markets. believe which European to better our our are As great of normal this advance markers in as and the use of indication between
diagnostic have development product Beyond a powerful ago, new The patient it in importance clinical instruments, stratification clinical for Suncor mentioned few to our used of supporting we studies, drugs, new being as also and evaluations AML, in regions strong expect addition a panel uptake. for is are a tool minutes the for the will crisp and research applications. and gaining I
us mission will develop technologies making products is the lives patients of that drives and our we that that are such depend excited and This part contributions. high-performing are our us medicine. of who the practice and on contributions of to enhance of All the important research to critical gratified and new doctors manufacture
include Regarding peer-reviewed publications, that technology. our
momentum We to of peer-reviewed bringing SITEC, speaks of to the to to there all-time this our We offerings scientific were validates our platform scientific achievement during committed are products. our with advancing the publications remarkable the This research community. mentioning alone, that importance XXX X,XXX. to innovative and publications of remain pleased the quarter number report
at As of an relapse. Cancer example stopping for researchers of paper one cancer research Institute metastatic strategies these significant in [indiscernible] Nature, therapeutic the identified in our published how some efforts are
spend. longevity, certain a not stop divisions, does published replication T second to a research discovered The life publication suggesting extending scientists direction after for cell of in which Nature human conditions number
recently becoming the very the diseases. the important immune of level specimens tool of increasingly was and Full simultaneously increased demand and used full and is a running possible you in a of we instrument for X-laser availability system running single-cell special is was into markets one paper clinical cytometry XX-color accepted cytometry, half as in Another a of FSP to various many reporting emerging human of immune in what the limited monitoring. panel. have XQ, to the in states, profiling increasing the of samples on analyze only section been abstract understanding monitoring as as often a Due where an our about which panel paper Immune immunology journal this patients reinforces importance to
our to like of spend imaging discuss the progress business. would I flow a and Luminex with moment to cytometry Finally, integration
Luminex we into more reach, provides us. little although key we technological than customer business shared, have still cytometry range, flow steps only and of are months ahead have our the and base, contributions important now a the product integration and process to commercial X imaging As abilities, some
of and other provide application and marketing We a our employees the each demonstrations, for new programs due That already. product and commercial technologies lessons the is and specialists, all service we Amnis important perspective, other's completed personnel have Guava include all several products areas. technical and to milestones customer sales, from team them. products programs, Cytek have on commercial cross-trained Cytek From to members Luminex. training, our These
manufacturing our In required, service targeted at addition launched the cross-training Amnis, bit will technical to service and due cross-training, Guava take to teams, training we a products. integration of but a teams in longer plan The an quarter business we integration. transition, From a established progress the for integration, completion target base of are the product third good harmonization. have operations perspective, on making that and system we
medium term, we Over regarding X have the set the milestones acquisition.
customer revenue. existing next rate potentially the customers million on into sales least milestone growth X,XXX X purchase Amnis first sales products by in The unit $XXX This approaching the Amnis X corporate X average goal Psyches to focused is half over with accelerating additional the of base. of at Amnis to penetrating approximately generating Aurora targeting the of includes years,
cost integration with platform next plans, could is Guava product Guava's to future The microcapital development to asset attractive X second an milestone its customer evaluating potential is structure new, technology the the months access a within provide base. Northern Lights and untapped determine
X convert platform Lastly, existing part Northern the progress. [indiscernible] look the you it to updating aims strategic Life for our to as of growth to users integration HX. We forward on the
combination we year, realized Most that While the will contributions platform. value in each longer the introduce of importantly, we that as of on revenue we this of modest a think reminder, a be the the X expect a have new available represent term we products areas. primary real number acquisition will from technologies acquisition this in
of significant teams. And of and and challenges addition our made to the integrated forward the with we organization a solution that, Patrick as the clinical and our our there some from this navigated We Luminex. the opportunities with team analysis service technologies to improvement will on We details our remain members once look the of to will new again, around Next, cell to turn bounce In over they a we pleased expect push products our progress. complemented in customers quarter sales I'm are more the gross provide novel highly with finally, by significant cross-selling progress leverage has experienced customers. on efficiency the providing margin the team platform call to as all, we With luminous financials. macro discovery for scientific and SFP now continuing front. these complete focused our the I trained,
